Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation

Konda Sri Chaya  Reddy; Darna  Bhikshapathi; Jaini Pavan  Kumar

doi:10.1590/

Authors

Konda Sri Chaya Reddy Research Scholar, Bir Tikandrajit University, Canchipur, Manipur, India https://orcid.org/0009-0004-6567-5516
Darna Bhikshapathi Bir Tikandrajit University, Canchipur, Manipur, India https://orcid.org/0000-0002-5521-2137
Jaini Pavan Kumar Raffles University, Rajasthan, India https://orcid.org/0000-0001-7413-6312

DOI:

https://doi.org/10.1590/

Keywords:

Box-Behnken design, Cross-linker, Cyclodextrin, Solubility, Dabrafenib, Diphenyl carbonate, Quality by Design

Abstract

This research aims to create dabrafenib (DBF)-loaded nanosponges (NSPs) using β-cyclodextrin (β-CD) and diphenyl carbonate (DPC) as linker to improve oral bioavailability. DBF-loaded β-CD NSPs were synthesized by finely adjusting the molar ratio of β-CD to DPC and optimizing the stirring rate and duration using design methodology. After being loaded with DBF, the produced β-CD NSPs were characterized in terms of particle size, zeta potential (Z.P), polydispersity index (PdI), and drug entrapment efficiency (E.E). Studies on compatibility were carried out with FTIR (Fourier Transform Infrared Spectroscopy) and DSC (Differential Scanning Calorimetry). Permeability, in vivo, and in vitro experiments were performed on the improved NSPs and the pure medication. After optimizing DBF-loaded β-CD NSPs, a formulation with a mean size of 158.0 ± 7.2 nm, PdI of 0.282 ± 0.0044, and E.E of 86.23 ± 2.45% was obtained, based on the assessments indicated earlier. Zeta sizer, SEM, spectrum analysis, in vitro release, and pharmacokinetic tests were among the other analyses that further validated the optimization. An area under the curve (AUC0-t) of 7.95-fold greater and a C_max 7.356 times higher than those of the free drug was demonstrated by the optimized β-CD NSPs, which showed a notable boost. The use of DBF-loaded NSPs holds promise as an effective strategy for enhancing release and bioavailability in the treatment of melanoma.

Downloads

References

Ansari KA, Torne SJ, Vavia PR, Trotta F, Cavalli R. Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr Drug Deliv. 2011;8(2):194-202. doi:10.2174/156720111794479934.

» https://doi.org/10.2174/156720111794479934

Aldawsari MF, Alhowail AH, Anwer MK, Ahmed MM. Development of diphenyl carbonate-crosslinked cyclodextrin based nanosponges for oral delivery of baricitinib: formulation, characterization and pharmacokinetic studies. Int J Nanomed. 2023 Apr 27;18:2239-51.

Almutairy BK, Alshetaili A, Alali AS, Ahmed MM, Anwer MK, Aboudzadeh MA. Design of olmesartan medoxomil-loaded nanosponges for hypertension and lung cancer treatments. Polymers (Basel). 2021 Jul 2;13(14):2272.

Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech. 2011 Mar;12(1):279-86.

Anwer MK, Ahmed MM, Aldawsari MF, Iqbal M, Kumar V. Preparation and evaluation of diosmin-loaded diphenylcarbonate-cross-linked cyclodextrin nanosponges for breast cancer therapy. Pharmaceuticals. 2023 Jan; 16(1): 19.

Bagul US, Nazirkar MV, Mane AK, Khot SV, Tagalpallewar AA, Kokare CR. Fabrication of architectonic nanosponges for intraocular delivery of Brinzolamide: An insight into QbD driven optimization, in vitro characterization, and pharmacodynamics. Int J Pharm. 2024 Jan;650:123746.

Committee for Medicinal Products for Human Use (CHMP) Assessment report Neofordex. 2015.

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. Multidisciplinary Digital Publishing Institute; 2018 10:57.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun;417(6892):949-54.

Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15(1):11-22.

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-901

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med. 2010 Aug;363(9):809-19.

Kalam MA, Iqbal M, Alshememry A, Alkholief M, Alshamsan A. Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate. Mol 2022 Apr;27(7):2326.

Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, et al. Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study. Clin Ther. 2011 Dec;33(12):2038-53.

Liu X, Li W, Xuan G. Preparation and characterization of β-cyclodextrin nanosponges and study on enhancing the solubility of insoluble nicosulfuron. In: IOP Conference Series: Materials Science and Engineering. IOP Publishing; 2020 Mar;774(1):012108.

Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics. 2000 Jul;50(1):3-12.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/ K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017 Jul;28(7):1631-9.

Mendes C, Wiemes BP, Buttchevitz A, Christ AP, Ribas KG, Adams AIH, et al. Investigation of β-cyclodextrin-norfloxacin inclusion complexes. Part 1. Preparation, physicochemical and microbiological characterization. Expert Rev Anti Infect Ther. 2015 Jan;13(1):119-29

Mendes C, Meirelles GC, Barp CG, Assreuy J, Silva MAS, Ponchel G. Cyclodextrin based nanosponge of norfloxacin: Intestinal permeation enhancement and improved antibacterial activity. Carbohydr Polym. 2018 Sep;195:586-92.

Moin A, Roohi NKF, Rizvi SMD, Ashraf SA, Siddiqui AJ, Patel M, et al. Design and formulation of polymeric nanosponge tablets with enhanced solubility for combination therapy. RSC Adv. 2020 Sep;10(57):34869-84.

Neerati P, Kumar Bedada S. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. Pharmacol Reports. 2015 Apr 1;67(2):339-44.

Omar SM, Ibrahim F, Ismail A. Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste. Saudi Pharm J. 2020 Mar 1;28(3):349-61.

Palanati M, Bhikshapathi DVRN. Development, characterization and evaluation of entrectinib nanosponges loaded tablets for oral delivery. Int J Appl Pharm. 2023 Nov;15(6):269-81.

Pham LM, Poudel K, Phung CD, Nguyen TT, Pandit M, Nguyen HT, et al. Preparation and evaluation of dabrafenib-loaded, CD47-conjugated human serum albumin-based nanoconstructs for chemoimmunomodulation. Colloids Surfaces B Biointerfaces. 2021 Dec;208:112093.

Radovic J, Maksimovic-Ivanic D, Timotijevic G, Popadic S, Ramic Z, Trajkovic V, et al. Cell-type dependent response of melanoma cells to aloe emodin. Food Chem Toxicol. 2012 Sep;50(9):3181-9.

Rai SK, Gunnam A, Mannava MKC, Nangia AK. Improving the Dissolution Rate of the Anticancer Drug Dabrafenib. Cryst Growth Des. 2020 Mar;20(2):1035-46.

Rangaraj N, Pailla SR, Chowta P, Sampathi S. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability. AAPS PharmSciTech . 2019 Oct 28;20(8):326

Real DA, Bolaños K, Priotti J, Yutronic N, Kogan MJ, Sierpe R, et al. Cyclodextrin-modified nanomaterials for drug delivery: Classification and advances in controlled release and bioavailability. Pharmaceutics. Multidisciplinary Digital Publishing Institute; 2021 Dec;13(12): 2131.

Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987 Jun;5(1):37-42.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med . 2015 Jan;372(1):30-9.

Running L, Espinal R, Hepel M. Controlled release of targeted chemotherapeutic drug dabrafenib for melanoma cancers monitored using surface-enhanced Raman scattering (SERS) spectroscopy. Mediterr J Chem. 2018;7(1):18-27.

Russi M, Valeri R, Marson D, Danielli C, Felluga F, Tintaru A, et al. Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer. Eur J Pharm Sci. 2023 Jan;180:106311.

Sampathi S, Prajapati S, Junnuthula V, Dyawanapelly S. Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension. Pharmaceutics. 2022 Sep;14(9):1947.

Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm . 1997 Nov;157(2):171-9.

Shah PP, Mashru RC, Thakkar AR, Badhan AC. Effect of chitosan crosslinking on bitterness of artemether using response surface methodology. J Pharm Pharmacol. 2008;60(4):421-427. doi:10.1211/jpp.60.4.0003.

» https://doi.org/10.1211/jpp.60.4.0003

Shah PP, Mashru RC, Thakkar AR, Badhan AC. Effect of chitosan crosslinking on bitterness of artemether using response surface methodology. J Pharm Pharmacol . 2010 Feb;60(4):421-7.

Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: A critical review. Carbohydrate Polymers. 2017 Oct;173:37-49.

Swaminathan S, Vavia PR, Trotta F, Cavalli R. Nanosponges encapsulating dexamethasone for ocular delivery: Formulation design, physicochemical characterization, safety and corneal permeability assessment. J Biomed Nanotechnol. 2013 Jun;9(6):998-1007.

Tejashri G, Amrita B, Darshana J. Cyclodextrin based nanosponges for pharmaceutical use: A review. Acta Pharmaceutica. Hrvatsko Farmaceutsko Drustvo; 2013; 63: 335-58.

Tiwari K, Bhattacharya S. The ascension of nanosponges as a drug delivery carrier: preparation, characterization, and applications. J Mater Sci Mater Med. 2022 Mar 4;33(3):28.

Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv [Internet]. 2010;17(6):419-25.

Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein Journal of Organic Chemistry. Beilstein-Institut; 2012;8:2091-9.

Utzeri G, Matias PMC, Murtinho D, Valente AJM. Cyclodextrin-Based Nanosponges: Overview and Opportunities. Vol. 10, Frontiers in Chemistry. Frontiers Media S.A.; 2022 Jan; 10:859406.

Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design., AAPS Journal. 2014 Jul; 16(4): 771-783.

Zidan MF, Ibrahim HM, Afouna MI, Ibrahim EA. In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. Drug Dev Ind Pharm. 2018 Aug;44(8):1243-53.

Unlocking Dabrafenib’s Potential

A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Issue

Section

License

How to Cite